Free Trial

Embecta Q2 2023 Earnings Report

Embecta logo
$18.68 -0.13 (-0.69%)
As of 01/17/2025 04:00 PM Eastern

Embecta EPS Results

Actual EPS
$0.75
Consensus EPS
$0.50
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A

Embecta Revenue Results

Actual Revenue
$277.10 million
Expected Revenue
$263.85 million
Beat/Miss
Beat by +$13.25 million
YoY Revenue Growth
N/A

Embecta Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Embecta Earnings Headlines

Embecta management to meet with BTIG
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
BTIG upgrades Embecta Corporation (EMBC) to a Buy
See More Embecta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Embecta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Embecta and other key companies, straight to your email.

About Embecta

Embecta (NASDAQ:EMBC), a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

View Embecta Profile

More Earnings Resources from MarketBeat